

## WORKSHOP

# Eye Drops from Human Origin

May 11-13, 2022 in Vienna, Austria



Cellular Therapies  
Working Party

Participation fee

€ 500



### When?

May 11th – 13th, 2022



### Where?

Venue Gesellschaft der Ärzte in Wien  
– Billrothhaus, Frankgasse 8, 1090  
Wien, Austria

### Goals of the Meeting:

This Workshop will provide a forum for **scientists, regulatory authorities, ophthalmologists and transfusion experts** on the usage, quality, clinical need and manufacture of eye drops from human origin. Selected scientific lectures from well-known experts will be presented.

Key discussions to find commonalities in production and quality issues include the latest scientific knowledge. The aim is to reach consensus on classification, validation and standardization of these products. The active participation from various regulatory agencies will also be an important emphasis of this workshop. Ample time shall be provided for a highly stimulating personal discussion:

- To exchange knowledge between eye specialists, transfusion specialists & regulators.
- To enhance knowledge of eye physicians on properties of EDHO and its regulatory requirements
- To enhance knowledge of transfusion specialists on serum eye drops, the clinical need, patient's needs
- To develop a common ground for the regulation of EDHO

### Who can attend?

- REGULATORY AUTHORITIES
- MANUFACTURERS OF EDHO
- BLOOD ESTABLISHMENTS
- TRANSFUSION MEDICINE SPECIALISTS
- OPHTHALMOLOGIST
- RESEARCHERS
- VENDORS

## More details

**Start of Meeting:** Wednesday May 11, 9:00 AM

**End of Meeting:** Friday May 13, 4:00 PM

**Participation fee:** €500 for clinicians and scientists; special fees apply to (members of) companies - inquiries to: [edho@gabriel.science](mailto:edho@gabriel.science)

**Participants:** Limited to max. 120 persons.

Restrictions due to COVID may apply.

## Sponsors



## REGISTRATION

[www.isbtweb.org/isbt-working-parties/cellular-therapies/edho2022](http://www.isbtweb.org/isbt-working-parties/cellular-therapies/edho2022)

## Organizers



**Thierry Burnouf**

Global Blood Safety WP Secretary, Cellular Therapies Steering Cmte. member, Vice-Dean, Taipei Medical University, Taiwan



**Christian Gabriel**

Cellular Therapies WP Steering Cmte. member, Ludwig Boltzmann Inst. for Experimental and Clinical Traumatology, Vienna, Austria



**Reinhard Henschler**

Cellular Therapies WP Steering Cmte. member. Director, Inst. of Transfusion Medicine bei University Hospital Leipzig, Germany



**Jutta Horwath-Winter**



**Mickey Koh**

Cellular Therapies WP Chair, Director, Stem Cell Transplantation at St George's hospital and Medical School, London, UK



**Denese Marks**

ISBT Regional Director Western Pacific, ISBT BC WP Chair, Assoc. Prof, University of Sydney, Australia; Australian Red Cross LifeBlood Service



**Katharina Schallmoser**

Paracelsus Medical University Salzburg, Austria

## Wednesday May 11

---

### Basics

- Lacrimal gland, Meibomian glands, Corneal regeneration
- Composition of tears, tear flow
- Properties of serum, platelet lysate, extracellular vesicles

Discussion: physiological properties & what is comparable

### Diseases of the eye

- Dry eye syndrome, GVHD, rare diseases of the anterior eye
- Neurotrophic keratopathy, Sjögren's Syndrome Post-surgery complications

Discussion: Where is the clinical need for EDHO?

### Properties and Pharmacology of eye drops

- Regulatory environment of pharmaceutical eye drops
- Pharmaceutical eye drops for the treatment of dry eye disease
- New products and developments

Discussion: what is currently in use, how does it compare to EDHO?

## Friday May 13

---

### Clinical outcomes

- Platelet lysate – clinical studies
- Cord blood
- Effects of EDHO on dry eye disease, Sjögren's syndrome
- Post LASIK and postoperative outcomes
- Evidence based use of EDHO

Discussion: which products meet clinical requirements and which data support the use of EDHO

### Regulatory requirements

Discussion: regulations overview and commonalities worldwide

Wrap up, final discussion and conclusions

## Thursday May 12

---

### Donation of EDHO and production of serum eye drops

- Donor requirements of eye drops: Are all donors eligible for autologous donation?
- How to produce autologous serum eye drops
- How to produce allogeneic serum eye drops
- Quality testing
- Dilution, packaging, labelling, storage, patient's perspective

Discussion: Key elements for serum eye drops-production, current requirements

### Production of new EDHO

- Eye drops from cord blood, human milk, platelet lysate, allogeneic and autologous

Discussion: production standards and differences to serum eye drops

### Quality issues

- Testing of growth factors, impurities, microbiology and general testing Discussion: which tests for which products?

Discussion: what is currently in use, how does it compare to EDHO?

**ATTEND SCIENTIFIC  
LECTURES FROM  
WELL-KNOWN EXPERTS  
AND DISCUSS ABOUT  
DONATION OF EDHO  
AND MUCH MORE.**

**REGISTER NOW**